Introduction
============

The entirety of *Impatiens balsamina* plants (balsam, LIB) have been widely used in Traditional Chinese Medicine to treat rheumatism, isthmus and crural aches, fractures, superficial infections, fingernail inflammation, etc. \[[@B1-molecules-13-00220]\]. Modern chemical and pharmacological studies have identified flavonol and naphthoquinone derivatives, some of which have strong antimicrobial \[[@B2-molecules-13-00220]\], anti-anaphylaxis \[[@B3-molecules-13-00220], [@B4-molecules-13-00220]\], anti-inflammatory \[[@B5-molecules-13-00220]\] as well as itch alleviating and anti-dermatitis activities, as the main chemical components of this plant \[[@B6-molecules-13-00220]\]. Moreover, in some areas of China, people ingest this plant as a vegetable or anti-cancer herb, although there are currently no reports confirming the efficacy of this practice. A pilot study demonstrated that LIB has *in vitro* anti-tumor activity against the HepG2 human hepatocellular carcinoma cell line. We now report the isolation of the active fractions using a MTT assay-guided fractionation and identified the positive spots using TLC. The *in vitro* anti-tumor activity of the active fractions was also assessed. Finally, we purified and identified the active component of the fraction displaying the highest activity.

Results and Discussion
======================

TLC analyses were performed using silica gel G plates. The results presented in [Figure 1](#molecules-13-00220-f001){ref-type="fig"} show that the PEF, CHF and CHE share some of the same spots contained within the black rectangle ([Figure 1](#molecules-13-00220-f001){ref-type="fig"}-b), especially the dark and bright spots (see arrows in [Figure 1](#molecules-13-00220-f001){ref-type="fig"}-a). On the other hand, the ethyl acetate (EAF) and *n*-butanol (BUF) fractions as well as the EAF, BUF and water (WAF) ones also share some common spots, as marked by the blue and yellow rectangles, respectively. In addition, there were few common spots between those shared by the PEF, CHF and CHE groups and those shared by the EAF, BUF, and WAF fractions. These results were confirmed using several different solvent eluent systems (data not shown).

MTT assays were performed following the protocol described in the Experimental section. The results indicated that the PEF, CHF and CHE fractions all had some *in vitro* anti-tumor activity against HepG2 cells, with the PEF fraction possessing the strongest activity, having a cell inhibition ratio of approximately 80% at a concentration of 50 mg/L, but there were too many common spots among the three of them to determine which spot active was the source of the observed activity. In contrast, the EAF, BUF and WAF fractions did not show any proliferation inhibition activity towards the HepG2 cells (data not shown). Consequently, only the PEF, CHF and CHE fractions were selected for further study.

![TLC display of the different fractions of LIB.](molecules-13-00220-g001){#molecules-13-00220-f001}

The dark and bright spots were the most likely candidates, as the red spots are usually caused by chlorophyll, but this still needed to be confirmed. Unfortunately, the available quantities of both PEF and CHF fractions were limited. The CHE fraction shared almost all the same spots with PEF and CHF and was plentiful enough to perform further separations. Thus, we used silica gel column chromatography and elution with a chloroform-methanol (9.5:0.5) system to further separate the CHE fraction into six sub-fractions: CHE1\~CHE6 (see details in [Figure 2](#molecules-13-00220-f002){ref-type="fig"}-a).

![TLC analysis of CHE sub-fractions.](molecules-13-00220-g002){#molecules-13-00220-f002}

MTT results revealed that only the CHE2 sub-fraction exhibited inhibitory activity. Moreover, its activity was even stronger than that of the PEF fraction ([Figure 3](#molecules-13-00220-f003){ref-type="fig"}). Comparing [Figure 2](#molecules-13-00220-f002){ref-type="fig"}-b,c with [Figure 1](#molecules-13-00220-f001){ref-type="fig"}-a, b, we can easily determine that the dark spot in the red rectangle (see [Figure 1](#molecules-13-00220-f001){ref-type="fig"}-b) is the positive spot. Additionally, we confirmed that these dark spots contained two substances (black and yellow spots, as seen in the green rectangle) using two more different developer systems.

![MTT results for the CHE sub-fractions.](molecules-13-00220-g003){#molecules-13-00220-f003}

Cells in 96-wells (2×10^4^ cells/well) were treated with different concentrations of CHE2 for 24 h, and curcumin was used as a positive control. The results indicated that CHE2 possessed a strong cell inhibition effect, with an IC~50~ = 6.47 ± 0.05 mg/L, as compared to curcumin (IC~50~ = 13.95 ± 0.11 mg/L). As shown in [Figure 4](#molecules-13-00220-f004){ref-type="fig"}, the inhibition effect was dose dependent.

![Cell inhibition effect of CHE2 compared with that of curcumin.](molecules-13-00220-g004){#molecules-13-00220-f004}

Rechromatography of fraction CHE-2 and recrystallization yielded an active single component. TLC confirmed that it corresponded to the dark spot in [Figure 2](#molecules-13-00220-f002){ref-type="fig"}-b, as marked by a black arrow. This compound was then identified as 2-methoxy-1,4-naphthoquinone (MNQ) by m.p., UV, MS and ^13^C- and ^1^H-NMR spectra. To reconfirm the anti-tumor activity of the final compound, we compared its HepG2 inhibition ratio with that of the CHE and CHE-2 fractions and curcumin. The MTT results in [Table 1](#molecules-13-00220-t001){ref-type="table"} show that MNQ possessed the highest activity with an IC~50~= 6.08 ± 0.08 mg/L, and that there was no significant difference with the activity of CHE2. We also determined that MNQ corresponded to 97.2% of the total CHE2 fraction,in agreement with the HPLC results (data not shown). These results concluded that MNQ is the main active component of CHE2 and with intensive anti-tumor activity against HepG2 cells *in vitro*.

molecules-13-00220-t001_Table 1

###### 

IC~50~ of the components against HepG2 cells in *vitro*.

  Components   IC~50~ (mg/L)
  ------------ ---------------
  CHE          41.5 ± 0.15
  CHE2         6.51 ± 0.10
  MNQ          6.08 ± 0.08
  Curcumin     14.18 ± 0.07

Because only the PBF and CHF fractions also contain this dark spot ([Figure 1](#molecules-13-00220-f001){ref-type="fig"}), only these fractions possess HepG2 inhibition activity. Several studies have revealed that 2-methoxy-1,4-naphthoquinone possesses notable antimicrobial activity. Little *et al*. \[[@B9-molecules-13-00220]\] first isolated this compound from *Impatiens balsamina* L. and found that it had anti-fungal activity as well as low phytotoxicity. Kang \[[@B10-molecules-13-00220]\] and Yang \[[@B2-molecules-13-00220]\] reported that both gram-positive and gram-negative bacteria strains were sensitive to 2-methoxy-1,4-naphthoquinone. Furthermore, Yang \[[@B2-molecules-13-00220]\] found that it was more effective than amphotericin B on seven human pathogenic fungal strains, some of which are resistant to amphotericin B and fluconazole. These findings validated the plant *Impatiens balsamina* L. as an antimicrobial herb.

Liu *et al.* \[[@B11-molecules-13-00220]\] reviewed naphthoquinones and their artificial derivatives on anti-tumor activity and showed that many correlated compounds had promising future applications. Our *in vitro* research indicated for the first time that the 2-methoxy-1,4-naphthoquinone compound had intensive inhibition activity in HepG2 cells, with an IC~50~ of cell inhibition effect of 6.08 ± 0.08 mg/L. Our work implies that the Chinese herb *Impatiens balsamina* does indeed have some anti-tumor bioactivities. This finding will greatly benefit the clinical use of *Impatiens balsamina* in Chinese medicine and suggests that 2-methoxy-1, 4-naphthoquinone could be a potent anti-tumor drug candidate.

Experimental
============

General
-------

Melting points were measured with a WRS-1 Digital Melting Point Apparatus \[Shanghai Physical Optical Instrument Factory (SPOIF), P.R. China\]. For the UV spectra 2-methoxy-1,4-naphthoquinone (1.0 mg) was dissolved in methanol and diluted to a volume of 10 mL with methanol, then 100 µL of this solution was to a new volumetric flask, and the volume made up to 1 mL with methanol and the spectra were recorded on an Ultraspec 2000 UV/visible spectrophotometer (Pharmacia Biotech).; MS data were recorded on a Bruker Esquire 3000 plus spectrometer. NMR spectra were recorded in CDCl~3~ (50.0 mg of 2-methoxy-1,4-naphthoquinone dissolved in 0.5 mL of solvent) on a Bruker Avance DMX 500 MHz spectrometer operating at 500 MHz (^1^H) or 125 MHz (^13^C), respectively. Curcumin (94% purity) was obtained from Sigma Chemical Co. (St. Louis, MO, USA). HPLC analyses were carried out on a Agilent 1100 series HPLC (Agilent Technologies, Palo Alto, CA, USA) equipped with a DAD 1100 diode array detector.

Plant material
--------------

*Impatiens balsamina* was grown in our lab and was authenticated by Professor Yao Zhensheng. The leaves of *Impatiens balsamina* were collected in August 2006, dried at room temperature for 2 weeks and then stored for further use.

Preparation of extracts
-----------------------

Dried leaves (200 g) were crushed, soaked with 55% alcohol (1500 mL) for 24 h and then reflux extracted for 40 min (1500 mL × 3). Extracts were filtered and vacuum evaporated; the residues were then suspended using distilled water and divided into five portions that were extracted systematically with the following solvents: petroleum ether (PEF), chloroform (CHF), ethyl acetate (EAF), *n*-butanol (BUF) and water (WAF). In addition, 200 g dried leaves were directly reflux extracted twice using chloroform (1500 mL/time). Next these extracts were filtered, combined, vacuum evaporated and the residue (CHE, 7.8 g) was dried for further use.

MTT test
--------

Human hepatocellular carcinoma cell line HepG2 purchased from the Cell Bank of The Chinese Academy of Science (Shanghai, P.R. China) was grown in RPMI-1640 medium (Gibco/Invitrogen Corp., Carlsbad, CA, USA) containing 10% FCS, 100 units/mL penicillin (Sigma, St. Louis, MO, USA) and 50 µg/mL streptomycin (Sigma) and was incubated at 37°C in 5% CO~2~. Cells in 96-wells (2×10^4^ cells/well) were treated with the different LIB fractions for 24 h. All the extracts and fractions were dissolved in DMSO, and then diluted with RPMI-1640 medium to obtain the required concentration before use, and cells grown in medium containing an equivalent final volume of DMSO (\< 0.1% v/v) served as a vehicle control. At the end of treatment, 20 μL of fresh serum-free medium containing MTT (5 mg/mL) reagent was added to each well. Cells were incubated for 4 h at 37°C, and the medium was then carefully aspirated from the wells. Cells were lysed by addition of 200 μL DMSO, and the optical density (OD) at 570 nm was determined using a Bio-Tek PowerWave 340 microplate scanning spectrophotometer. Data are reported as the average of at least three replicates.

Differential display analysis of TLC spots
------------------------------------------

Samples were dissolved in the appropriate organic solvent, applied to the silica gel G plates (10 cm × 20 cm activated at 105°C for 1 h) and developed with several different suitable solvent systems (see details in the Results and Discussion section). The plates were dried in a fume hood, photographed under an ultraviolet lamp and then were further sprayed by reagents to better display the components from the different fractions.

Additional fractionation of active fractions
--------------------------------------------

Active fractions or sub-fractions were further separated by silica gel chromatography, eluting with corresponding eluent, and monitored by TLC (see details in the Results and Discussion section).

Active component identification
-------------------------------

A portion of sub-fraction CHE2 (90.6 mg) was re-chromatographed on silica gel using a petroleum ether-acetone (8:2) system es eluent and the isolated product was recrystallized from CHCl~3~ to yield the active component as light yellow crystals, 88.1 mg (97.2%). TLC confirmed that it was the dark spot in [Figure 2](#molecules-13-00220-f002){ref-type="fig"}-b, as marked by a black arrow. In addition, HPLC showed a single peak (date not shown). The compound was identified as 2-methoxy-1,4-naphthoquinone (MNQ), according to the following data: m.p. 183-183.5°C; UV λ~MeOH~ (log ε) ([Figure 5](#molecules-13-00220-f005){ref-type="fig"}): 215 (3.95), 241 (4.21), 246 (4.21), 275 (4.16), 329 (3.46); EIS-MS ([Figure 6](#molecules-13-00220-f006){ref-type="fig"}) *m/z*: 210.8 \[M + Na\] ^+^; ^13^C-NMR ([Figure 7](#molecules-13-00220-f007){ref-type="fig"}) δ: 180.3 (C-1), 160.6 (C-2), 110.1 (C-3), 185.0 (C-4), 126.9 (C-5), 134.5 (C-6), 133.5 (C-7), 126.4 (C-8), 131.3 (C-9), 132.2 (C-10), 56.6 (C-11); ^1^H-NMR ([Figure 8](#molecules-13-00220-f008){ref-type="fig"}) δ: 3.90 (3H, s, H-2-OCH~3~), 6.16 (1H, s, H-3), 7.73 (2H, m, H-5,8) 8.10 (2H, m, H-6,7), which were all consistent with those described previously \[[@B2-molecules-13-00220],[@B7-molecules-13-00220],[@B8-molecules-13-00220]\].

![UV spectrum of MNQ.](molecules-13-00220-g005){#molecules-13-00220-f005}

![Positive ion EIS-MS spectrum of MNQ.](molecules-13-00220-g006){#molecules-13-00220-f006}

![^13^C-NMR spectrum of MNQ.](molecules-13-00220-g007){#molecules-13-00220-f007}

![^1^H-NMR spectrum of MNQ.](molecules-13-00220-g008){#molecules-13-00220-f008}

*Sample Availability*: Contact the authors.
